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Abstract
Background: AATD is one of the most common inherited disorders in the World. However, it
is generally accepted that AATD in North African populations is not a risk factor for lung and/or
liver disease, based on a number of small studies. We therefore planned a screening study for
detection of AATD in patients with OLD in a cohort of patients from Kairouan in central Tunisia.
Methods: One hundred twenty patients with OLD (asthma, emphysema, COPD) were enrolled in
the screening programme. Laboratory diagnosis for AATD was performed according to current
diagnostic standards.
Results:  We found that 6/120 OLD patients carried an AAT deficient allele, 1 PI*MZ, 1
PI*MPlowel, 3 PI*MMmalton, 1 PI*MMwurzburg.
Conclusion: this pilot study demonstrated that alleles related to deficiency of AAT are not absent
in the Tunisian population, and that rare AATD variants prevailed over commonest PI*Z variant.
These results would support a larger scale screening for AATD in Tunisia.
Background
Alpha 1 antitrypsin (AAT) is an acute phase glycoprotein
predominantly derived from the liver, and its major bio-
logical function is to inhibit neutrophil elastase [1]. AAT,
a highly polymorphic protein with more than 120 vari-
ants known to date [2] is coded by a gene, called
SERPINA1, located on chromosome 14q31-32.3 within
the SERPIN cluster [3]. The SERPINA1 PI*M alleles code
for the commonest normal AAT variants, whereas PI*S
and PI*Z are the most common deficiency alleles associ-
ated with reduced concentrations of plasma AAT. Never-
theless, there are at least 30 SERPINA1  alleles rarely
detected, other than the PI*Z and the PI*S alleles, which
are associated with significantly reduced AAT levels [4-6].
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Inherited deficiency of AAT (AATD) is one of the most
common genetic disorders in the world, and is associated
with an increased risk of developing lung and, to a lesser
extent, liver disease [7]. Individuals homozygous for the
PI*Z allele usually have an AAT level in the region of 0.35
g/L [3] and are at high risk for the development of emphy-
sema [8], asthma [9], chronic bronchitis and bronchiecta-
sis [10]. However, heterozygous individuals with PI*S
and PI*Z mutation (or rare mutations) showing a more
protective AAT level (> 0,8 g/L) [3] can also be at increased
risk for lung disease, depending on multiple environmen-
tal factors, such as smoking, occupational exposure, and
environmental exposure.
Epidemiology studies showed that highest prevalence of
PI*ZZ related AATD is recorded among Northern Europe-
ans and populations with North European background
[11]. Notwithstanding, during the last few years, based on
estimates from allele frequencies obtained in available
cohort studies, it has been suggested that the Z variant is
not only common in Caucasians, but also among other
ethnic groups worldwide [12,13].
A total of 30 cohorts have been investigated for AATD in
the African continent. Twenty four cohorts, having a total
of 4,718 individuals, were in Sub-Saharian Africa [14], 6
cohorts with a total sample size of 1,735 have been inves-
tigated in the north African populations [15-20], Three of
them in Tunisia: in the Tunisian population, the PI*Z
allele, previously considered as virtually absent [15,16],
has then been detected once on the heterozygous state in
a total cohort of 1,168 individuals (allele frequency
0.04%) [17]. However, none of the previous surveys in
Tunisia has looked at rare, non-S and non-Z SERPINA1
variants, which have been hypothesised to be particularly
frequent in the Mediterrenean area, where PI*Z allele fre-
quency is reduced [4]. We therefore aimed this paper at
investigating AATD variants in a Tunisia area, targeting a
cohort of obstructed individuals, in which the diagnosis
of AATD has been recommended accoding to the ATS/ERS
document [21].
Methods
Study subjects
Upon approval by the local Ethical Committee, patients
with obstructive lung disease (OLD: asthma, emphysema,
COPD), referred to the pulmonary disease department in
Kairouan regional hospital (central Tunisia) from June
2006 to September 2006, were enrolled in the screening
programme. Diagnosis of obstructive lung disease was
obtained by symptoms, radiology, lung function exami-
nations and allergy history.
Quantitative determination of AAT level
AAT concentration measurement was performed on
plasma samples with a rate immune turbidimetric
method (Konelab 20, Thermo Clinical Labsystem, Fin-
land), using a polyclonal anti-human AAT antibody
(Thermo Electron Corporation, Finland). A calibrator
(Specical, Thermo Electron Corporation, Finland) with an
assigned AAT value was used as a standard. A control
(Specitrol, Thermo Electron Corporation, Finland) with
an assigned AAT value was used after a predefined reac-
tion number. Plasma samples for the turbidimetric assay
are diluted by the instrument 1:10 (AAT reading range,
0.23–4.4 g/L). The turbidimetry of antigen-antibody com-
plex was measured at 360 nm. Values obtained are
regressed according to the calibration curve, and
expressed as g/L.
Molecular diagnosis of AATD
DNA extracted from the white blood cells of all subjects
by standard methods, was submitted to genotyping for Z
and S SERPINA1  alleles, by PCR-RFLP, as previously
described [22]. According to published diagnostic algo-
rythm [23], samples negative for Z and S alleles, but with
inconsistent AAT level/genotype were submitted to
sequencing of SERPINA1exons II, III, IV, and V, as previ-
ously described [24].
Results
One hundred twenty subjects with OLD were enroled in
this study. There were 115 males and 5 females, mean age
(SD) 49.2 (9.5) years (range 34–81). The large majority of
patients were smokers (84.1%). As far as the OLD pheno-
type was concerned, there were 49 COPD (40.8%), 48
emphysema (40%), and 23 asthma patients (19.2%).
Mean (SD) plasma AAT level was 1.74 g/L (0.63) (range
0.81 to 3.3). Plasma AAT level distribution is shown in fig-
ure 1.
SERPINA1 S and Z allele genotyping, performed in all
OLD subjects, allowed the detection of one PI*MZ indi-
vidual (plasma AAT level: 0.81 g/l, consistent with the
detected genotype).
Nevertheless, some subjects negative for PI*S and PI*Z
allele detection, displayed plasma AAT levels consistent
with intermediate AATD; in particular, 4 subjects dis-
played plasma AAT level < 1 g/L [mean (SD) 0.91 g/L
(0.02)]. According to our protocol for detection of rare
AATD variants, such samples with inconsistent AAT level/
genotype were suitable for sequencing [4,24]. In the
absence of reference values of plasma AAT in the general
population from Tunisia, we decided to submit to
sequencing, DNA samples from subjects with plasma AAT
levels < 1.5 g/L, rather than the usual cut-off of 1.13 g/L
[25]. We therefore sequenced 24 DNA samples (plasmaOrphanet Journal of Rare Diseases 2009, 4:12 http://www.ojrd.com/content/4/1/12
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AAT level range: 0.89–1.48). We found that 5 subjects
were heterozygous for rare deficiency variants: 3 subjects
carried the PI* MMmalton, 1 the PI*MPlowell, and 1 the
PI*MMwurzburg genotypes. Figure 2 summarises the
results of genotyping/sequencing.
Discussion
Meta-analysis of available data showed that SERPINA 1
PI*S and PI*Z deficiency alleles are extremely rare in
North African populations [12,13]. Recent investigations
in the Tunisian population confirmed the low frequency
of AATD common deficiency variants in the general pop-
ulation and healthy subjects (1078 subjects investigated:
15 PI*MS detected (PI*S: 0.7%; PI*Z: 0%)) [15-17], as
well as in COPD patients (90 subjects investigated: 1
PI*SS and 1 PI*MZ detected (PI*S: 1%; PI*Z: 0.5%))
[17]. The present study, performed in 120 patients with
OLD, confirms these data: PI*S allele was not seen,
whereas PI*Z was detected only once on the heterozygous
state (frequency 0.4%).
In this study, we extended the SERPINA1 gene investiga-
tion to variants not detectable by rapid PI*S and PI*Z gen-
otyping: by this strategy, we found 5 more deficiency
variants (frequency as a whole 2%) detected on the heter-
ozygous state. Such a condition of a relatively higher fre-
quency of rare than common AATD variants, is shared by
Central – Southern regions of Italy, in which PI*Mmalton
and PI*Mprocida variants seem to prevail over PI*Z [4].
Interestingly, the PI*Mmalton variant, detected in three
unrelated individuals in this paper, is the commonest
AATD variant in Sardinia, where the PI*Z variant is
detected very rarely [4,26]. A novel SERPINA1 Null muta-
tion, first described in an Egyptian family, and for that rea-
son called Q0*cairo [27] has been repeatedly detected in
unrelated individuals from regions of Southern Italy. Pop-
ulation admixture due to migration occurred in ancestral
periods, as well as contacts for commercial purposes in
more recent centuries are likely to be responsible for dis-
semination of rare AATD variants in the Southern Medi-
terrenean basin. Table 1 summarizes the rare variants
reported in the Mediterranean basin, as well as the muta-
tions types, the cellular defect and the related clinical data
[4,28-30].
This study strengthens the concept that for a correct labo-
ratory diagnosis of AATD, there is a need of a combination
of biochemical and biomolecular methods [24], other-
AAT plasma level distribution in OLD patients Figure 1
AAT plasma level distribution in OLD patients. The 
expected normal values (in green) were calculated using 
Rankit proportional estimation.
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Schematic representation of the genotyping/sequencing results Figure 2
Schematic representation of the genotyping/sequencing results.
OLD subjects
n = 120
mean AAT (SD): 1.74 g/l  (0.63)
AAT range: 0.81-3.3
genotyping for 
S and Z S or Z allele
genotype (n)   AAT (g/l)
MZ         1    0.81
cut-off : 1.5 g/l 
Rare AATD variant
mean AAT (SD): 0.96 g/l  (0.12)
genotype (n)   AAT (g/l)
PI*MMmalton 3     0.89; 0.94;1.18
PI*MPlowell 1     0.9
PI*MMwurzburg 1     0 .91
n = 24
mean AAT (SD): 1.24 g/l  (0.17)
AAT range: 0.89-1.48
sequencing of exons 
2,3,4,5Orphanet Journal of Rare Diseases 2009, 4:12 http://www.ojrd.com/content/4/1/12
Page 4 of 5
(page number not for citation purposes)
wise rare AATD variants will be missed [5]. These prelim-
inary data also confirm the usefulness of enrolling
patients with OLD in a screening programme for AATD.
According to the ATS/ERS statement's evidence based rec-
ommendations, all subjects with COPD and asthma
should be submitted to diagnostic testing for AATD [21].
In this paper, although no subjects with severe AATD defi-
ciency were detected, we found six out of 120 subjects
(5%) carrying the so called "intermediate deficiency", that
means heterozygosity with one normal PI*M allele and
one severe AATD allele [mean (SD) plasma AAT level:
0.93 g/L (0.12)]. These findings are consistent with the
hypothesis that intermediate AATD, such as PI*MZ or
equivalent genotypes, represent a risk factor for develop-
ing COPD [20]. Recent meta-analysis [31] reported the
increase in risk of COPD in PI*MZ heterozygous individ-
uals (OR for PI*MZ versus PI*MM (normal genotype)
was 2.31 (95% CI 1.60 to 3.35)).
Severe AATD diagnosis in the North African countries
might be beneficial to the treatment of patients with the
introduction of AAT replacement therapy in these popula-
tions. Furthermore, AATD carrier diagnosis might provide
genetic counseling to persons who are planning a preg-
nancy or are in the prenatal period [21]. In addition,
awareness of carrying a gene that may increase the suscep-
tibility to COPD may be an additional factor for a success-
ful enrolment of patients in smoking cessation
programmes [32].
Conclusion
This investigation, performed for the first time with cur-
rent diagnostic standards in a North African population,
highlights the implication of AATD in development of
OLD in this area, whereas previous data excluded a role
for AATD in the African continent. This would suggest
that, similarly to what happens in the Caucasians, also in
Northern Africans AATD is an underdiagnosed condition,
and therefore investigations in larger sample sizes would
be advisable. It seems also likely that targeted detection
strategy to identify affected individuals produces a rate of
detecting disease higher than the population-based
screening programs. Such approach may also contribute
to change the widespread concept concerning the AAT
deficiency epidemiology in North African and others pop-
ulations.
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